{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:25:54Z","timestamp":1788193554720,"version":"build-2803163510"},"reference-count":60,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2023,1,18]]},"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:p>The introduction of calcitonin gene-related peptide monoclonal antibodies represents a step forward in preventive migraine treatment as the first agents to target the underlying pathogenesis of migraine. In trials they act more quickly, have better long-term adherence and appear to be better tolerated than other treatments. Major disadvantages are their high cost and unknown safety in pregnancy and in cardiovascular disease. To mitigate these concerns, they should be used according to guidance produced by professional bodies, with defined starting and stopping criteria. We do not yet know whether they are more effective than standard care; many patients may still be better treated by other means, in particular addressing lifestyle factors and medication-overuse headache.<\/jats:p>","DOI":"10.1136\/pn-2022-003592","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T13:21:30Z","timestamp":1675862490000},"page":"200-207","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Calcitonin gene-related peptide (CGRP) monoclonal antibodies for migraine"],"prefix":"10.1136","volume":"23","author":[{"given":"Nicola J","family":"Giffin","sequence":"first","affiliation":[{"name":"Neurology, Royal United Hospital, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"key":"2025090410562580000_23.3.200.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31460-X"},{"key":"2025090410562580000_23.3.200.2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414547138"},{"key":"2025090410562580000_23.3.200.3","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410330109"},{"key":"2025090410562580000_23.3.200.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030505"},{"key":"2025090410562580000_23.3.200.5","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779543"},{"key":"2025090410562580000_23.3.200.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"2025090410562580000_23.3.200.7","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"2025090410562580000_23.3.200.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"2025090410562580000_23.3.200.9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4853"},{"key":"2025090410562580000_23.3.200.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709038"},{"key":"2025090410562580000_23.3.200.11","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"key":"2025090410562580000_23.3.200.12","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled regain study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"2025090410562580000_23.3.200.13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"key":"2025090410562580000_23.3.200.14","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"key":"2025090410562580000_23.3.200.15","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.4.490"},{"key":"2025090410562580000_23.3.200.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01678.x"},{"key":"2025090410562580000_23.3.200.17","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3B study","volume":"392","author":"Reuter","year":"2018","journal-title":"The Lancet"},{"key":"2025090410562580000_23.3.200.18","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1177\/0333102418788347","article-title":"Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study","volume":"38","author":"Ashina","year":"2018","journal-title":"Cephalalgia"},{"key":"2025090410562580000_23.3.200.19","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (focus): a randomised, double-blind, placebo-controlled, phase 3B trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"The Lancet"},{"key":"2025090410562580000_23.3.200.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30279-9"},{"key":"2025090410562580000_23.3.200.21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","article-title":"Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (deliver): a multi-arm, randomised, double-blind, placebo-controlled, phase 3B trial","volume":"21","author":"Ashina","year":"2022","journal-title":"Lancet Neurol"},{"key":"2025090410562580000_23.3.200.22","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1111\/ene.15364","article-title":"Erenumab in chronic migraine: experience from a UK tertiary centre and comparison with other real-world evidence","volume":"29","author":"Khalil","year":"2022","journal-title":"Eur J Neurol"},{"key":"2025090410562580000_23.3.200.23","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-020-01214-2","article-title":"Improvements in pain, medication use and quality of life in onabotulinumtoxina-resistant chronic migraine patients following erenumab treatment-real world outcomes","volume":"22","author":"Talbot","year":"2021","journal-title":"J Headache Pain"},{"key":"2025090410562580000_23.3.200.24","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/ene.14715","article-title":"Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial","volume":"28","author":"Ashina","year":"2021","journal-title":"Eur J Neurol"},{"key":"2025090410562580000_23.3.200.25","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-022-01408-w","article-title":"Comparing the relative and absolute effect of erenumab: is a 50 % response enough? Results from the esteemen study","volume":"23","author":"Ornello","year":"2022","journal-title":"J Headache Pain"},{"key":"2025090410562580000_23.3.200.26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/ane.13472","article-title":"Refractory migraine profile in CGRP-monoclonal antibodies scenario","volume":"144","author":"Silvestro","year":"2021","journal-title":"Acta Neurol Scand"},{"key":"2025090410562580000_23.3.200.27","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-022-02714-1","article-title":"Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial","volume":"22","author":"Ailani","year":"2022","journal-title":"BMC Neurol"},{"key":"2025090410562580000_23.3.200.28","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1001\/jama.2021.7665","article-title":"Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack","volume":"325","author":"Winner","year":"2021","journal-title":"JAMA"},{"key":"2025090410562580000_23.3.200.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813440"},{"key":"2025090410562580000_23.3.200.30","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S1474-4422(22)00294-0","article-title":"Safety and efficacy of erenumab in patients with trigeminal neuralgia in denmark: a double-blind, randomised, placebo-controlled, proof-of-concept study","volume":"21","author":"Schott Andersen","year":"2022","journal-title":"Lancet Neurol"},{"key":"2025090410562580000_23.3.200.31","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419844711"},{"key":"2025090410562580000_23.3.200.32","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25831"},{"key":"2025090410562580000_23.3.200.33","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/head.13316","article-title":"A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina","volume":"58","author":"Depre","year":"2018","journal-title":"Headache"},{"key":"2025090410562580000_23.3.200.34","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/head.14208","article-title":"Risk of hypertension in erenumab-treated patients with migraine: analyses of clinical trial and postmarketing data","volume":"61","author":"Dodick","year":"2021","journal-title":"Headache"},{"key":"2025090410562580000_23.3.200.35","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/0333102418776017","article-title":"Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers","volume":"39","author":"de Hoon","year":"2019","journal-title":"Cephalalgia"},{"key":"2025090410562580000_23.3.200.36","doi-asserted-by":"crossref","DOI":"10.1186\/s42466-020-00057-1","article-title":"Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: addition to the S1 guideline: therapy of migraine attacks and prevention of migraine. recommendations of the germany society of neurology and the german migraine and headache society","volume":"2","author":"Diener","year":"2020","journal-title":"Neurol Res Pract"},{"key":"2025090410562580000_23.3.200.37","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1177\/0333102419829007","article-title":"Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine-a meta-analysis of randomized controlled trials","volume":"39","author":"Xu","year":"2019","journal-title":"Cephalalgia"},{"key":"2025090410562580000_23.3.200.38","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.203"},{"key":"2025090410562580000_23.3.200.39","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00404-014-3303-8","article-title":"Calcitonin gene- and parathyroid hormone-related peptides in normotensive and preeclamptic pregnancies: a nested case-control study","volume":"290","author":"Yadav","year":"2014","journal-title":"Arch Gynecol Obstet"},{"key":"2025090410562580000_23.3.200.40","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/0333102420983292","article-title":"Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: analysis of the who pharmacovigilance database","volume":"41","author":"Noseda","year":"2021","journal-title":"Cephalalgia"},{"key":"2025090410562580000_23.3.200.41","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/03331024211053571","article-title":"Erenumab versus topiramate for the prevention of migraine-a randomised, double-blind, active-controlled phase 4 trial","volume":"42","author":"Reuter","year":"2022","journal-title":"Cephalalgia"},{"key":"2025090410562580000_23.3.200.42","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-020-01173-8","article-title":"The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the halo cm study","volume":"21","author":"Silberstein","year":"2020","journal-title":"J Headache Pain"},{"key":"2025090410562580000_23.3.200.43","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/0333102420966658","article-title":"Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine","volume":"41","author":"Dodick","year":"2021","journal-title":"Cephalalgia"},{"key":"2025090410562580000_23.3.200.44","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-021-01328-1","article-title":"Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months","volume":"22","author":"Caronna","year":"2021","journal-title":"J Headache Pain"},{"key":"2025090410562580000_23.3.200.45","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1007\/s10072-021-05105-5","article-title":"Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study","volume":"42","author":"Cainazzo","year":"2021","journal-title":"Neurol Sci"},{"key":"2025090410562580000_23.3.200.46","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","article-title":"Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial","volume":"92","author":"Tepper","year":"2019","journal-title":"Neurology"},{"key":"2025090410562580000_23.3.200.47","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.788159","article-title":"Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to onabotulinumtoxina treatment for migraine prevention in adult patients with chronic migraine","volume":"12","author":"Mechtler","year":"2021","journal-title":"Front Neurol"},{"key":"2025090410562580000_23.3.200.48","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2211-17.2017"},{"key":"2025090410562580000_23.3.200.49","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419873675"},{"key":"2025090410562580000_23.3.200.50","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-022-01393-0","article-title":"Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2B\/3 trials in Japanese and Korean patients","volume":"23","author":"Takeshima","year":"2022","journal-title":"J Headache Pain"},{"key":"2025090410562580000_23.3.200.51","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-018-0923-6","article-title":"Early onset of efficacy with erenumab in patients with episodic and chronic migraine","volume":"19","author":"Schwedt","year":"2018","journal-title":"J Headache Pain"},{"key":"2025090410562580000_23.3.200.52","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/head.13691","article-title":"Rapid onset of effect of galcanezumab for the prevention of episodic migraine: analysis of the evolve studies","volume":"60","author":"Detke","year":"2020","journal-title":"Headache"},{"key":"2025090410562580000_23.3.200.53","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-020-01127-0","article-title":"A prospective real-world analysis of erenumab in refractory chronic migraine","volume":"21","author":"Lambru","year":"2020","journal-title":"J Headache Pain"},{"key":"2025090410562580000_23.3.200.54","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-320242"},{"key":"2025090410562580000_23.3.200.55","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/03331024211046617","article-title":"Migraine evolution after the cessation of CGRP (-receptor) antibody prophylaxis: a prospective, longitudinal cohort study","volume":"42","author":"Raffaelli","year":"2022","journal-title":"Cephalalgia"},{"key":"2025090410562580000_23.3.200.56","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/ene.15260","article-title":"Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine","volume":"29","author":"Iannone","year":"2022","journal-title":"Eur J Neurol"},{"key":"2025090410562580000_23.3.200.57","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/03331024211048765","article-title":"Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study","volume":"42","author":"Overeem","year":"2022","journal-title":"Cephalalgia"},{"key":"2025090410562580000_23.3.200.58","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000518899","article-title":"Early experiences in switching between monoclonal antibodies in patients with nonresponsive migraine in Spain: a case series","volume":"85","author":"Patier Ruiz","year":"2022","journal-title":"Eur Neurol"},{"key":"2025090410562580000_23.3.200.59","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.neurol.2020.04.027","article-title":"Monoclonal antibodies blocking CGRP transmission: an update on their added value in migraine prevention","volume":"176","author":"Schoenen","year":"2020","journal-title":"Rev Neurol (Paris)"},{"key":"2025090410562580000_23.3.200.60","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-022-01431-x","article-title":"European headache federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update","volume":"23","author":"Sacco","year":"2022","journal-title":"J Headache Pain"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/pn-2022-003592","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T17:56:51Z","timestamp":1757008611000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/pn-2022-003592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,8]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,5,25]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1136\/pn-2022-003592"],"URL":"https:\/\/doi.org\/10.1136\/pn-2022-003592","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,8]]}}}